Search
toremifene (Fareston)
Indications:
-> metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor unknown tumors
Pharmacokinetics:
-> metabolized in the liver by cyt P450 3A4
Drug interactions:
1) any drug that inhibits cyt P450 3A4 may increase levels of toremifene
2) any drug that induces cyt P450 3A4 may diminish levels of toremifene
Mechanism of action:
- selective estrogen receptor modulator (SERM)
Related
breast cancer
cytochrome P450 3A4 (cytochrome P450 C3, nifedipine oxidase, P450-PCN1, NF-25, CYP3A4)
General
antineoplastic endocrine agent
Properties
MISC-INFO: elimination route LIVER
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California, Drug update, 9/2000
- Prescriber's Letter 13(3): 2006
Cytochrome P450 drug interactions
Detail-Document#: 220233
(subscription needed) http://www.prescribersletter.com